MSME (Udyam registered) Ministry of MSME
- Category
- Small (2023-24)
- Udyam number
- UDYAM-TS-30-0000777
Accrete Pharmaceuticals Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹41.49 Cr
▲ 19% YoY
Net profit · FY 2025
₹9.61 Cr
Net margin 23.2%
EBITDA · FY 2025
₹14.6 Cr
EBITDA margin 35.2%
Authorised capital
₹5 Cr
Registered with MCA
Paid-up capital
₹4.5 Cr
Issued & subscribed
Open charges
₹8.84 Cr
Satisfied ₹7.65 Cr
Company age
22 yrs
Est. 2004
Employees · EPFO
52
Provident fund records
About Accrete Pharmaceuticals Private Limited
Data last updated:
Accrete Pharmaceuticals Private Limited is a private limited company based in Hyderabad, Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 23 July 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG2004PTC043737. Its GSTIN is 36AAFCA2804G1Z2 (Telangana). The company holds 2 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹4.5 Cr. It is led by directors including Maheshwar Parsi and Srinivas Aita.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 5 – 70 First Floor Near Andhra Bank Street No.8 Habsiguda, Hyderabad, Telangana, India – 500007.
As per the financials filed for FY 2025, the company reported a revenue of ₹41.49 Cr, a growth of 19% compared to the previous year. For the same year it recorded a net profit of ₹9.61 Cr (net margin 23.2%) and EBITDA of ₹14.6 Cr (EBITDA margin 35.2%). Revenue has grown at a compounded annual rate (CAGR) of 13% over three years and 18% over five years.
The company has about 52 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Accrete Pharma. As per MCA filings, the company has open charges of ₹8.84 Cr and satisfied charges of ₹7.65 Cr on record. The company has 10 deals on record (7 secondary share transfers, 3 funding rounds), with disclosed funding of ₹3.59 Cr; the latest was in March 2014. Its 8 peer companies in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 3 smaller; the largest is Hi Tech Biosciences India Private Limited with revenue of ₹41.75 Cr.
Accrete Pharmaceuticals Private Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-30-0000777). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website accretepharma.com.
Company details
CIN U24239TG2004PTC043737
Registration Number 043737
Incorporation Date 23 July 2004
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-TS-30-0000777
CIN history
Accrete Pharmaceuticals has one previous CIN (Corporate Identification Number): U24239AP2004PTC043737. The current CIN is U24239TG2004PTC043737, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239TG2004PTC043737 | Current |
| U24239AP2004PTC043737 | Previous |
Recognitions & Rankings of Accrete Pharmaceuticals
Contact details
Accrete Pharmaceuticals Private Limited's registered office is in Hyderabad, Telangana. Its website is accretepharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address5 – 70 First Floor Near Andhra Bank Street No.8 Habsiguda, Hyderabad, Telangana, India – 500007
- IndustryPharma, API Manufacturers
To see the full contact details of Accrete Pharmaceuticals Private Limited, buy the company report.
Comprehensive company report
Accrete Pharmaceuticals Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Accrete Pharmaceuticals operates one associated brand: Accrete Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures bulk drug intermediates for oncology pharmaceuticals in India. | accretepharma.com |
Business activity
The main business activity of Accrete Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Accrete Pharmaceuticals Private Limited, buy the company report.
Financials of Accrete Pharmaceuticals Private Limited
FY 2025 filings availableAccrete Pharmaceuticals Private Limited reported revenue of ₹41.49 Cr (up 19% YoY) for FY 2025.
Revenue · FY 2025
₹41.49 Cr ▲ 19%
Net profit · FY 2025
₹9.61 Cr margin 23.2%
EBITDA · FY 2025
₹14.6 Cr margin 35.2%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 19%
3 years · compounded
▲ 13%
5 years · compounded
▲ 18%
EBITDA CAGR growth
1 year
▲ 27%
3 years · compounded
▲ 28%
5 years · compounded
▲ 46%
Revenue has grown at a compounded annual rate (CAGR) of 18% over five years, including 19% growth in the latest year. EBITDA rose 27% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹14.6 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹9.61 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 35.2% | ||||
| Net Profit Margin | 23.2% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Accrete Pharmaceuticals Private Limited, buy the company report.
Board of directors of Accrete Pharmaceuticals Private Limited
Accrete Pharmaceuticals has 4 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Maheshwar Parsi | Director | 10 May 2010 | 16 Years 5 Months | Current |
| Srinivas Aita | Director | 10 May 2010 | 16 Years 5 Months | Current |
| Sukarna Dodle | Director | 23 Jul 2004 | 22 Years 3 Months | Current |
| Aileni Dhruva | Director | 14 May 2014 | 12 Years 5 Months | Current |
Peer comparison
Accrete Pharmaceuticals Private Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Hi Tech Biosciences India Private Limited | ₹41.75 Cr (FY 2025) | 24.0% | Pune, Maharashtra, India | |||
| Jai Lara Drugs Private Limited | ₹41.75 Cr (FY 2025) | 9.0% | Hyderabad, Telangana, India | |||
| Polydrug Laboratories Private Limited | ₹41.72 Cr (FY 2024) | 238.0% | Mumbai, Maharashtra, India | |||
| Phanicare Pharmaceuticals Private Limited | ₹41.7 Cr (FY 2024) | -18.0% | Hyderabad, Telangana, India | |||
| Qualikems Lifesciences Private Limited | ₹41.7 Cr (FY 2025) | 13.0% | Vadodara, Gujarat, India | |||
| Accrete Pharmaceuticals Private Limitedthis company | ₹41.49 Cr (FY 2025) | ₹9.61 Cr | 23.2% | 19.0% | 52 | Hyderabad, Telangana, India |
| Assurgen Pharma Private Limited | ₹41.36 Cr (FY 2025) | -3.0% | Visakhapatnam, Andhra Pradesh, India | |||
| Relixir Pharmaceuticals Private Limited | ₹41.19 Cr (FY 2023) | 48.0% | Hyderabad, Telangana, India | |||
| Elixir Pharma Chem Private Limited | ₹41.04 Cr (FY 2025) | 86.0% | Ahmedabad, Gujarat, India |
To see the full peer comparison of Accrete Pharmaceuticals Private Limited, buy the company report.
Auditor
Accrete Pharmaceuticals Private Limited is audited by G.K. DATAR & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| G.K. DATAR & CO. | FY 2023 | 022277 |
Shareholding
The shareholding of Accrete Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Accrete Pharmaceuticals Private Limited, buy the company report.
Charges & borrowings
Open charges
₹8.84 Cr
Satisfied charges
₹7.65 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 24 May 2024 | 100933260 | Sidbi | ₹1.84 Cr | Open | |
| 07 Jul 2006 | 10014917 | State Bank of India | ₹7 Cr | Open | |
| 16 Mar 2022 | 100549483 | Sidbi | ₹98 Lakh | Satisfied | |
| 23 Oct 2020 | 100380690 | State Bank of India | ₹95 Lakh | Satisfied | |
| 12 Mar 2020 | 100332307 | Sidbi | ₹1.7 Cr | Satisfied |
To see the full charge records of Accrete Pharmaceuticals Private Limited, buy the company report.
Total charge records: 8 View all charges
Deals & funding
Accrete Pharmaceuticals Private Limited has 10 deals on record (7 secondary share transfers, 3 funding rounds), with disclosed funding of ₹3.59 Cr; the latest was in March 2014.
Total deals
10
Secondary share transfers
7
Funding rounds
3
Disclosed funding
₹3.59 Cr
Deals on record (5 of 10)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2014 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: an individual |
| Mar 2013 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: 3 individuals |
| Mar 2013 | Funding round | ₹83.7 Lakh | Investors: 4 individuals |
| Mar 2011 | Funding round | ₹95.7 Lakh | Investors: Quiver Technologies, 3 individuals |
| May 2010 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
To see the full deal history of Accrete Pharmaceuticals Private Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Accrete Pharmaceuticals Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
Credit ratings & regulatory alerts
Accrete Pharmaceuticals Private Limited was last rated by Crisil on 14 Sep 2020.
| Rating agency | Rated on | Rating |
|---|---|---|
| Crisil | 14 Sep 2020 |
To see the full credit ratings and regulatory alerts of Accrete Pharmaceuticals Private Limited, buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Accrete Pharmaceuticals Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Accrete Pharmaceuticals Private Limited has a workforce of 52 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.
Employee count
52
Active EPFO establishments
1
GST
Accrete Pharmaceuticals has 2 GST registrations: 1 active and 1 cancelled or inactive.
Total GSTINs
2
Active
1
Cancelled / inactive
1
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAFCA2804G1Z2 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Accrete Pharmaceuticals Private Limited, buy the company report.
Recent activity
Accrete Pharmaceuticals Private Limited has 11 board changes on record since 2004: 4 appointments and 7 cessations. The latest: Aileni Dhruva ceased to be Additional Director on 30 Sep 2014.
AGM
Accrete Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Accrete Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Charges
A charge registered on 12 Mar 2020 via Charge ID 100332307 with Sidbi was fully satisfied on 04 Mar 2025.
Charges
A charge registered on 12 Apr 2018 via Charge ID 100172896 with Sidbi was fully satisfied on 25 Jun 2024.
Charges
A charge with Sidbi amounted to Rs. 1.84 Cr with Charge ID 100933260 was registered on 24 May 2024.
Charges
A charge registered on 23 Oct 2020 via Charge ID 100380690 with State Bank Of India was fully satisfied on 21 Feb 2024.
Charges
A charge registered on 16 Mar 2022 via Charge ID 100549483 with Sidbi was fully satisfied on 14 Aug 2023.
Charges
A charge registered on 02 Nov 2017 via Charge ID 100132184 with Sidbi was fully satisfied on 08 Mar 2023.
Charges
A charge with Sidbi amounted to Rs. 0.98 Cr with Charge ID 100549483 was registered on 16 Mar 2022.
Charges
A charge with State Bank Of India amounted to Rs. 0.95 Cr with Charge ID 100380690 was registered on 23 Oct 2020.
Charges
A charge with Sidbi amounted to Rs. 1.70 Cr with Charge ID 100332307 was registered on 12 Mar 2020.
Charges
A charge registered on 23 Jul 2013 via Charge ID 10443031 with Small Industries Development Bank Of India. was fully satisfied on 10 Mar 2020.
17 earlier events are in the company report.
Frequently asked questions
Accrete Pharmaceuticals is an active private limited company based in Hyderabad, Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 23 July 2004 (22+ years old) and is registered under CIN U24239TG2004PTC043737.
Accrete Pharmaceuticals has 4 current directors:
- Maheshwar Parsi - Director
- Srinivas Aita - Director
- Sukarna Dodle - Director
- Aileni Dhruva - Director
The latest financial statements of Accrete Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Accrete Pharmaceuticals is 36AAFCA2804G1Z2, registered in Telangana. The company has 2 GST registrations in all, of which 1 is active and 1 is cancelled or inactive.
The CIN (Corporate Identification Number) of Accrete Pharmaceuticals is U24239TG2004PTC043737. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Accrete Pharmaceuticals was incorporated on 23 July 2004, making it 22+ years old. It is registered with the Registrar of Companies, Hyderabad.
Accrete Pharmaceuticals has 10 deals on record (7 secondary share transfers, 3 funding rounds), with disclosed funding of ₹3.59 Cr; the latest was in March 2014.
The peers of Accrete Pharmaceuticals by revenue are Hi Tech Biosciences India Private Limited, Jai Lara Drugs Private Limited, Polydrug Laboratories Private Limited, Phanicare Pharmaceuticals Private Limited, Qualikems Lifesciences Private Limited and 3 more, all in the Pharma industry (API Manufacturers, Pharmaceuticals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Aileni Dhruva ceased to be Additional Director on 30 Sep 2014. Aileni Dhruva was appointed as Director on 14 May 2014. Aileni Shyam Sunder Reddy ceased to be Additional Director on 30 Sep 2011. Accrete Pharmaceuticals has 11 board changes on record in total.
Yes, Accrete Pharmaceuticals is registered as a small enterprise under Udyam registration (number: UDYAM-TS-30-0000777).
Accrete Pharmaceuticals can be reached through the website accretepharma.com. Its registered office is in Hyderabad, Telangana, India.